An increasing proportion of MRSA isolates are resistant to additional antimicrobial agents, which complicates therapy [3]. The identification of S. aureus strains with intermediate and complete resistance to vancomycin has raised particular concern. Children with infections due to such organisms should be managed in consultation with an expert in infectious diseases.

Clinical trials evaluating antimicrobial agents for invasive methicillin-resistant S. aureus (MRSA) infections in children are lacking. The treatment approach suggested in this topic review is based on case series, in vitro susceptibility testing, and the clinical experience of experts [4-6].

To continue reading this article, you must log in with your personal, hospital,
or group practice subscription. For more information or to purchase a personal subscription, click below on
the option that best describes you:

Gorwitz RJ, Jernigan DB, Powers JH, et al. Strategies for clinical management of MRSA in the community: Summary of an experts' meeting convened by the Centers for Disease Control and Prevention. 2006. www.cdc.gov/ncidod/dhqp/pdf/ar/CAMRSA_ExpMtgStrategies.pdf (Accessed on September 13, 2011).